an update on the prosper trial: focusing on nonmetastatic crpc
Published 6 years ago • 1.1K plays • Length 21:25Download video MP4
Download video MP3
Similar videos
-
2:34
asco: bone effects fuel optimism for prostate ca drug
-
5:49
aua: drug slows bone mets in prostate cancer
-
32:22
emerging treatment options for non - metastatic crpc sept 2018
-
0:57
dr. dorff on choosing between therapies in nonmetastatic crpc
-
1:19
nonmetastatic crpc: meeting an unmet need
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
1:45
dr. choudhury on antiandrogen treatment selection in nonmetastatic crpc
-
5:50
mfs: a new endpoint for nonmetastatic crpc
-
26:28
advances in non-metastatic prostate cancer: navigating arpis and precision diagnostics
-
7:46
treating non-metastatic castrate resistant prostate cancer | ask a prostate expert, mark scholz, md
-
8:56
abiraterone in metastatic prostate cancer
-
6:50
ep. 6: identifying nonmetastatic crpc
-
3:06
enzalutamide in the context of nonmetastatic crpc
-
22:16
understanding non metastatic castration resistant prostate cancer with dr. hamilton
-
6:51
understanding nonmetastatic crpc: an overview
-
5:20
apalutamide in treating nonmetastatic crpc
-
0:44
dr. wise on the fda approval of apalutamide in non-metastatic crpc
-
5:55
the future of treatment for nonmetastatic crpc
-
1:00
castration resistant #prostatecancer | #markscholzmd #pcri
-
3:08
when to treat nonmetastatic crpc
-
2:24
delaying disease progression in early, non-metastatic crpc treatment
-
4:47
treatment challenges in nonmetastatic crpc